Optimal Neoadjuvant Approach for Resectable Esophageal Cancer in the Era of Immunotherapy.
Int J CancerMay 20, 2026 (epub)
Guo Lin, Fan Ge, Yunsong Liu et al.
✦ AI-curated · Sources linked
In 30 seconds
This network meta-analysis evaluated neoadjuvant immunotherapy strategies for resectable esophageal cancer, analyzing 41 trials with 4624 patients. The study found that neoadjuvant immunotherapy combined with chemoradiotherapy followed by surgery (nICRT+S) achieved the highest pathological complete response (pCR) rate, indicating superior efficacy compared to other approaches.
Key findings
- nICRT+S achieved the highest pCR rate among neoadjuvant strategies.
- nICT+S had the greatest probability of improving major pathological response (mPR) and objective response rate (ORR).
- The addition of immunotherapy or radiotherapy did not increase grade ≥ 3 treatment-related adverse events.
- Maintenance immunotherapy after surgery did not show additional survival benefits.
Why it matters
Understanding the optimal neoadjuvant approach for esophageal cancer is crucial for improving patient outcomes. This analysis provides insights into effective strategies that enhance tumor response while minimizing toxicity, guiding clinical decision-making.